Reimbursement scheme Forxiga®

General information

From September 1st 2021 onwards, Forxiga® (dapagliflozine) 10 mg for the treatment of adults with type 2 diabetes mellitus with a very high risk of cardiovascular disease is fully reimbursed by the health insurer.
With this reimbursement, the Reimbursement Solution TerugBetaalRegeling (TBR) of Forxiga® (dapagliflozin) 10 mg for patients with diabetes and a very high risk of cardiovascular disease will expire on 1 September 2021. For patients who do NOT fall under these new reimbursement conditions, a decision will be made in 6 months on the continuation and implementation of the current TBR and the current TBR will continue to apply.

Very high risk means:
• previously proven cardiovascular disease; and/or
• chronic kidney damage with
− eGFR 30-59 ml/min per 1.73m2 with moderately elevated albuminuria (ACR > 3 mg/mmol/l); or
− eGFR ≥ 60 ml/min per 1.73 m2 with severely elevated albuminuria (ACR>30 mg/mmol)

For a complete reimbursment overview of Forxiga® (dapagliflozine) 10 mg, click here.

Dose	Forxiga® 10mg
Type	Tablets
Active ingredient	DAPAGLIFLOZINE

Reimbursement

Conditions

Declarations of Forxiga® (dapagliflozin) 10 mg for patients with diabetes and a very high risk of cardiovascular disease, with an issue date between July 1st 2019 and September 1st 2021, can still be submitted to TBR Nederland until December 31, 2021. Prescriptions from the 1st of September will be fully reimbursed by the health insurer.

Who can submit a claim

Patients or their caregiver can claim the Personal Contribution for Forxiga® (dapagliflozine) 10mg online or by mail.
Pharmacists can only claim this medicine online on behalf of the patient.

From when till when can you submit a claim

You can only submit invoices for patients with diabetes and a very high risk of cardiovascular disease, with an issue date between July 1st 2019 and September 1st 2021. Invoices with an issue date between those dates can still be submitted to TBR Nederland until December 31, 2021.